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1 Prenatal patency of the ductus arteriosus is maintained by prostaglandin (PG) E2, conceivably in
concert with nitric oxide (NO). Local PGE2 formation is sustained by cyclooxygenase-1 (COX1) and
cyclooxygenase-2 (COX2), a possible exception being the mouse in which COX1, or both COXs, are
reportedly absent. Here, we have examined the occurrence of functional COX isoforms in the near-
term mouse ductus and the possibility of COX deletion causing NO upregulation.
2 COX1 and COX2 were detected in smooth muscle cells by immunogold electronmicroscopy, both
being located primarily in the perinuclear region. Cytosolic and microsomal PGE synthases (cPGES
and mPGES) were also found, but they occurred diffusely across the cytosol. COX1 and, far more
frequently, COX2 were colocalised with mPGES, while neither COX appeared to be colocalized with
cPGES.
3 The isolated ductus from wild-type and COX1/ mice contracted promptly to indomethacin
(2.8 mm). Conversely, the contraction of COX2/ ductus to the same inhibitor started only after a
delay and was slower.
4 NG-nitro-l-arginine methyl ester (l-NAME, 100 mm) weakly contracted the isolated wild-type
ductus. Its effect, however, increased three- to four-fold after deleting either COX, hence equalling
that of indomethacin.
5 In vivo, the ductus was patent in all mice foetuses, whether wild-type or COX-deleted. Likewise, no
genotype-related difference was noted in its postnatal closure.
6 We conclude that the mouse ductus has a complete system for PGE2 synthesis comprising both
COX1 and COX2. The two enzymes respond differently to indomethacin but, nevertheless, deletion of
either one results in NO upregulation. PGE2 and NO can function synergistically in keeping the ductus
patent.
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Introduction
It is known that prenatal patency and postnatal closure of the
ductus arteriosus are actively induced (Smith, 1998). Prosta-
glandin (PG) E2 plays a major role in both the conditions,
namely, through foetal life by exerting a potent relaxant effect
(Clyman, 1987; Coceani & Olley, 1988), possibly in conjunc-
tion with nitric oxide (NO) (Coceani et al., 1994; Momma &
Toyono, 1999; Seidner et al., 2001; Takizawa et al., 2001), and
after birth by abruptly withdrawing its action. Two synergistic
events occur during the immediate neonatal period that
account for the lesser efficacy of PGE2, viz, the fall in blood
levels of the compound (Challis et al., 1976; Clyman et al.,
1980; Jones et al., 1993) and the waning expression within the
ductus of PGE2 receptor subtypes subserving relaxation
(Bouayad et al., 2001). Based on this premise, much interest
has focused on the ontogeny of cyclooxygenase (COX), a key
enzyme in the PG synthetic pathway existing in two isoforms
(i.e. COX1 and COX2) (Smith et al., 1996). Studies, carried
out in the lamb and the pig, have shown that COXs develop
unevenly in the ductus, with COX1 preceding COX2 in the
course of gestation (Guerguerian et al., 1998; Takahashi et al.,
2000; Coceani et al., 2001). Hence, both COX1 and COX2
have been implicated in PGE2 formation at term, while COX1
has been assigned a predominant role in the premature
(Coceani et al., 2001). In contradiction with this scheme,
however, it has recently been reported that the mouse ductus
lacks COX1 at term gestation and may, at least in vivo, fail to
constrict to the dual COX1/COX2 inhibitor, indomethacin,
once its COX2 had been deleted (Loftin et al., 2001).
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Furthermore, another investigation could not detect either
COX in the same vessel or, at most, could demonstrate a
minimal, and reportedly insignificant, expression of the two
enzymes (Reese et al., 2000). The latter finding is in clear
contrast with our observation that indomethacin exerts a
potent constrictor effect on the isolated mouse ductus (Coceani
et al., 1999).
The present investigation was carried out to resolve these
apparent inconsistencies and gain, at the same time, a better
insight into the functional organisation of the PG synthetic
system in the ductus. This was achieved by examining the
occurrence in the term mouse ductus of the two COX isoforms
and the terminal enzymes for PGE2 synthesis (i.e. microsomal
and cytosolic PGE synthase; mPGES and cPGES) (Murakami
et al., 2000; Tanioka et al., 2000). Concomitantly, the effect of
indomethacin was assessed on the isolated vessel from wild-
type vs COX(1 or 2)-deleted animals. In addition, the possible
upregulation of the NO system upon COX deletion was
verified by testing on the same preparations the NO synthase
(NOS) inhibitor, NG-nitro-l-arginine methyl ester (l-NAME).
Experiments in vitro were complemented by a study in vivo in
which, using a whole-body freezing technique (Ho¨rnblad &
Larsson, 1967; Coceani et al., 1999), the calibre of the ductus
was monitored from the term foetal through the early neonatal
periods before and after deleting either COX isoform.
A preliminary account of this work has been reported
(Coceani et al., 2003).
Methods
Experiments were carried out in 129/B6 mice with COX1/
and COX2/ genotypes (Morham et al., 1995) (litter size, 2–
12; mean, 6), and wild-type C57/Bl6 mice (litter size 4–12;
mean, 7) provided a control after having confirmed in
preliminary experiments with the inhibitors (see below) that
they behave as the wild-type 129/B6 mice. COX2þ / mice
were also used in selected experiments. As expected, animals
from the various groups did not differ in general appearance
and, consequently, their genotype was verified on tail speci-
mens by PCR (Ballou et al., 2000). Surgical procedures and
experimental protocols were approved by the Animal Care
Committee of the Ministry of Health.
In vitro studies
Term foetal mice, both wild-type and gene-deleted (gestational
age, 19 days, body wt. 0.9–1.4 g, mean 1.1), were delivered by
Caesarean section under halothane anaesthesia and were killed
by cervical dislocation. The procedure for dissection of the
ductus arteriosus, normalisation of internal circumference and
mechanical record has been described previously (Coceani
et al., 1999). In brief, the animal was secured with its left side
up in a dissection chamber containing ice-cold Krebs solution
gassed with 5% CO2 in N2. Through a thoracotomy, the
ductus was exposed, separated from the adjoining large blood
vessels and then suspended onto 25-mm tungsten wires (Cooner
wire, Chatsworth, U.S.A.) inside an organ bath. The fluid of
the bath was gassed with gas mixtures containing 2.5 or 12.5%
O2 to mimic, respectively, the foetal and the neonatal
condition. Preparations were then equilibrated (about 60min
at 371C) with a minimal stretch being applied (all values in
mNmm1) (COX1/, 0.0470.001 (n¼ 8); COX2/,
0.0570.001 (n¼ 16); COX2þ /, 0.0570.001 (n¼ 11); wild-
type, 0.0470.0009 (n¼ 24)) and the attendant internal
circumference (C0) with the related resting dimensions
(Table 1) served as a reference for choosing the appropriate
load. Afterwards, tension was applied to attain an operating
circumference (i.e. C50) coinciding with the condition in vivo
(COX1/, 0.4970.008 (n¼ 8); COX2/, 0.4770.01
(n¼ 16); COX2þ /, 0.4670.007 (n¼ 11); wild-type,
0.5270.006 (n¼ 24); all values in mNmm1), and the actual
experiment was started following a second, 60–80-min period
of equilibration.
The study comprised two main protocols depending on
whether COX or NOS function was investigated. In protocol 1
(n¼ 33), indomethacin (2.8 mm) was added to the perfusion
fluid, and its effect was ascertained on basal tone at either 2.5
or 12.5% O2. Preliminary experiments with the wild-type
confirmed the occurrence of a concentration-dependent con-
traction to oxygen, mimicking in magnitude (0.1270.02,
0.2270.03 and 0.3970.04mNmm1 with 12.5, 30 and 95%
O2, respectively; n¼ 3) and pattern that of 129/SvEv mice (see
Coceani et al., 1999). In certain cases, the contraction to
indomethacin did not subside, or subsided only partially, after
the tissue had been returned to the control medium (see
Results). The tissue was then treated (5–7-min application)
with the relaxant sodium nitroprusside (SNP) (100 mm) in the
attempt of reversing this persistent response. The same
procedure was used with protocol 2 (n¼ 39), except for the
fact that l-NAME (100mm) was tested. In either protocol,
concentrations of the inhibitors were selected on the basis of
previous reports (Coceani et al., 1994; 1999), and treatment
lasted 60min or as long as required to achieve a maximal
effect. The contraction to the TXA2 analogue (0.1 mm)
provided in both cases a reference. In the majority of
experiments, only one protocol was used with each vessel.
However, when the two treatments were performed in
Table 1 Resting dimension of isolated ductus arteriosus from wild-type and COX-deficient term foetal mice
Dimension (mm) Wild-type (n¼ 25) COX1/ (n¼ 8) COX2/ (n¼ 16) COX2+/ (n¼ 11)
Internal diameter 17773 16274w 15574ww 15774ww
Vessel length*
Short side 52278 530719 466713ww 475717ww
Long side 54278 548719 483713ww 488717ww
Wall thickness 1870.6 2170.7 2070.6 1970.7
Values are mean7s.e.m. *Vessel length of the ductus arteriosus is uneven because of its insertion into aorta at an angle. Short side was
taken for normalisation of internal circumference and calculation of tension output (see In vitro studies). wvs wild-type, Po0.05 (Student’s
t-test); wwvs. wild-type, Po0.01 (Student’s t-test). Note that, in spite of its overall smaller size, the COX2/ ductus was outwardly normal
on light microscopy and had, specifically, a well-developed muscle layer (C. Ackerley and F. Coceani, unpublished data).
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succession, l-NAME was tested after indomethacin (interval,
2.5–3.5 h) and on the condition that the baseline had returned
to control values.
In vivo studies
Experiments were carried out in foetuses (gestational age, 19
days) or newborns (max. 12 h) depending on the protocol.
Animals (wild-type and COX-deleted) were delivered by
Caesarean section under halothane anaesthesia in the former
case, while in the latter they were used at different intervals
after a vaginal delivery. Time zero (i.e. the time at which
delivery was completed) was assessed for each animal in the
litter. Throughout the survival period, newborns were placed
on a warm metal plate (B371C) and were also heated with a
lamp. All animals were killed by cervical dislocation.
Changes in the ductus calibre through the transition from
the pre- to the postnatal condition were assessed by fixing the
vessel in situ with the whole-body freezing technique (Ho¨rn-
blad & Larsson, 1967; Coceani et al., 1999). Briefly, animals
were placed with their right side up in a Petri dish and were
covered with an embedding medium (Tissue-Tek optimum
cutting temperature compound; Sakura Finetek, Torrance,
U.S.A.). The dish with the animal was then wrapped with
aluminium foil and immersed in liquid N2. Once frozen,
specimens were stored at 201C for further work-up. To
prepare a block of tissue with the ductus, the carcass was freed
of its embedding in the frozen state. With a razor blade, soft
tissues covering the dorsum were removed, making certain that
the exposed surface would be parallel to the underlying
descending aorta and hence perpendicular to the ductus.
Serial, transversal sections (5-mm thick), progressing from this
cut through the whole length of the vessel, were obtained on a
Zeiss freezing microtome (model HM500 OM, Walldorf,
Germany) and were stained with 1% methylene blue. Care
was taken to collect a complete series of ductus sections.
Afterwards, each section was photographed with a CCD solid-
state camera (COHU San Diego, U.S.A.) and lumen area of
the ductus was measured with a MCID-M4 program (Brock
University, St Catharines, Canada). Both maximal and
minimal values of this area were retrieved from each series
for computation.
Preparation of total RNA and RT–PCR
Total RNA was isolated from the foetal ductus (gestational
age, 19 days; wild-type and COX1/) with the TriPure
Isolation Reagent (Roche Diagnostic Corporation, Indiana-
polis, U.S.A.), as recommended by the manufacturer, follow-
ing a modification of the method of Chomczynsky & Sacchi
(1987). Briefly, 30–40 specimens of ductus were pooled,
homogenised in TriPure solution (1ml) and then 0.2ml of
chloroform was added. The resulting mixture was centrifuged
(12,000 g; 15min at 41C), the aqueous phase was separated
and transferred to a tube where RNA was precipitated with
0.5ml of isopropanol. The precipitate was pelleted by
centrifugation (12,000 g; 10min at 41C), and the pellet was
washed with ethanol–water (7.5 : 2.5, by volume) before being
dissolved into sterile Rnase-free water. Any genomic DNA
contamination was subsequently removed by treatment with
Rnase-free Dnase I (Roche). RNA (1 mg) was reverse
transcribed with 1U of ThermoScript RT (Invitrogen Cor-
poration, Carlsbad, U.S.A.) in the presence of random
hexanucleotide primers according to the manufacturer’s
instructions. The cDNA product was used for the amplifica-
tion of COX1 (32 cycles), COX2 (35 cycles), eNOS (36 cycles),
iNOS (38 cycles) and nNOS (38 cycles). Forward/reverse
primers and general procedure were the same of early reports
for both COX (Zhang et al., 2002) and NOS (Kabayashi et al.,
2001; Winkler et al., 2001) isoforms. Cyclophilin (forward
primer: 50-AGTTCCATCGTGTCATCAAGG-30; reverse pri-
mer: 50-GTTTCTCCACTTCGATCTTGC-30; primers based
on the reported gene sequence, GenBank accession no.
NM-022563) was used as internal reference (see Haendler
et al., 1987) after confirming its steady expression through the
perinatal period (S. Barogi, unpublished data), and separate
samples being processed without cDNA ruled out any
contamination. Agarose gels (1.5% wv1) were stained with
ethidium bromide and the bands were quantified by NIH 1.60
software (National Institute of Health, Bethesda, U.S.A.).
Integrated densities were normalised to cyclophilin values for a
semiquantitative assessment of individual transcript levels.
Preliminary experiments confirmed that PCR conditions and
image analysis were in the linear range of detection.
Electron microscopy immunogold histochemistry
Wild-type foetal ductus specimens, which had been prepared in
the usual manner and pinned to a wax board, were fixed in 2 or
4% paraformaldehyde/0.1% glutaraldehyde in 0.1m phos-
phate buffer (PBS; pH 7.4). They were then rinsed thoroughly
with PBS before being stored at 41C in the same buffer
containing sodium azide (20mm). Specimens were subse-
quently infused with 2.3m sucrose and, after being trimmed
to a trapezoidal shape, were mounted on aluminium pins and
plunge frozen in liquid N2. Cryosections (901C) of approxi-
mately 100-nm thickness were prepared with a diamond knife
in a Reichert Jung Ultracut S microtome equipped with a
cryochamber. These ultrathin sections were transferred to
glow-discharged carbon-coated nickel grids by use of a loop of
molten sucrose. After any residual aldehyde had been
neutralised by treatment with 0.15% glycine–0.5% bovine
serum albumen (BSA) in PBS, sections were washed repeatedly
with BSA-supplemented PBS (0.5%) and were then incubated
with antiserum against COX1 (dilution, 1 : 50), COX2 (dilu-
tion, 1 : 200), mPGES (dilution, 1 : 10) or cPGES (dilution,
1 : 150). The antiserum was subsequently removed by repeated
rinsing with BSA-supplemented PBS, and specimens were
treated for 60min with gold-labelled goat anti-mouse im-
munoglobulin (particle diameter, 5 or 10 nm) (dilution, 1 : 20
for both). After another thorough wash with PBS/BSA and
distilled water in succession, sections were embedded in a thin
film of methylcellulose containing 0.2% of uranyl acetate and
then were viewed and photographed in a JEOL model 1230
(Peabody, U.S.A.) transmission electron microscope. Specifi-
city of binding was verified by omitting the primary antiserum
or by neutralising the primary antiserum with excess enzyme
protein (10 : 1 ratio). Gold particles were counted in smooth
muscle cells either at random within putative immunoreactive
regions (i.e., perinuclear and peripheral cytoplasm; see Coceani
et al., 2001) (5 fields cell1 at  25,000 magnification) or in the
whole cytoplasm (20 fields cell1 at  50,000 magnification).
The size of gold particles in the two analyses was, respectively,
10 and 5 nm. Number of cells examined in each specimen
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(n¼ 4) varied from a minimum of 25, when the plan of section
crossed the perinuclear cytoplasm, to a maximum of 43.
Possible colocalisation of COX and PGES enzymes was also
verified in a separate analysis of the perinuclear and peripheral
regions of the cell (three fields at  50,000 magnification for
each region; min. 50 cells per specimen) through dual tagging
with gold particles of different size (COX isozymes, 10 nm,
PGES isozymes, 5 nm). Quantification of particles in the entire
cytoplasm as well as in discrete regions of the cell (expressed in
both cases as particles mm2) was done with the Image ProPlus
morphometric programme (Media Cybernetics, Des Moines,
U.S.A.) on images being acquired via a digital camera (AMT,
Danver, U.S.A.) from the transmission electron microscope.
COX/PGES colocalisation was quantified by measuring the
ratio (in percentage) between COX-linked and free PGES.
Solutions and drugs
The Krebs medium had the following composition (mm): NaCl
118, KCl 4.7, CaCl2 2.5, KH2PO4 1, MgSO4 0.9, dextrose 11.1
and NaHCO3 25. Depending on the protocol, the solution was
bubbled with gas mixtures containing either no O2 or O2 in one
of two concentrations (2.5 and 12.5%) plus 5% CO2 and
balance N2. PO2 was measured with a Chiron gas analyser
(mod. 248, Halstead, U.K.) and was 1.0970.03, 2.1170.01
and 770.02 kPa (pH 7.4270.002) when gas mixtures were
used with 0, 2.5 and 12.5% O2, respectively.
Purified seminal vesicle COX1, placental COX2 (both from
sheep), mPGES and cPGES (both human type) were supplied
by Cayman (Ann Arbor, U.S.A.). COX1 and COX2 antisera
(courtesy of Merck Frosst, Montreal, Canada) and cPGES
antiserum (obtained from Cayman) were all polyclonal and
had been generated in the rabbit. mPGES antiserum (courtesy
of NIH Scor Program, Cell and Tissue Banking Resource,
Michigan State University, Ann Arbor, U.S.A.) was instead
monoclonal and was derived from a murine lymphoblast cell
line. Colloidal gold-labelled (particle diameter, 5 or 10 nm)
goat anti-rabbit or anti-mouse immunoglobulins were pur-
chased from Amersham (Piscatoway, U.S.A.).
The thromboxane A2 (TXA2) analogue 9,11-epithio-11,12-
methano-TXA2 (ONO-11113, courtesy of ONO Pharmaceu-
tical, Osaka, Japan) was dissolved in distilled ethanol
(5mgml1), and aliquots (stored at 701C) were diluted with
Tris buffer (pH 7.4). Indomethacin, a dual COX1/COX2
inhibitor (Sigma, St Louis, U.S.A), was also dissolved in
distilled ethanol (10mgml1) before preparation of the final
solution in the Krebs medium. Ethanol in the fluid bathing
isolated ductus preparations did not exceed 0.01% (indo-
methacin) or 0.001% (ONO-11113). The NOS inhibitor
l-NAME and SNP (both from Sigma) were dissolved directly
in saline. Precautions were taken to protect the SNP solution
from light. Doses of all compounds are given in molar
concentrations and refer to their final concentration in the
bath. Vehicle alone, without or with ethanol (see above), had
no effect on the vessel tone.
Analysis of data
Baseline contractile tension, which varied with the preparation
(see Results), refers to the net active tension (i.e., total tension
minus applied tension) developed by the preparation prior to
any treatment. Responses to test agents are given as the
fractional change from baseline.
Data are expressed as the mean7s.e.m. Comparisons were
made using a Student’s t-test or ANOVA, followed when
required by Duncan’s multiple-range test. Differences are
considered significant for Po0.05.
Results
mRNA analysis
The ductus arteriosus from the wild-type foetal mouse
expressed mRNA for both COX1 and COX2 at term gestation
(Figure 1, upper panel). Conversely, only one of the NOS
isoforms, eNOS mRNA, was detected in the same preparation
and its expression did not change appreciably upon deleting
COX1 (Figure 1, lower panel). Furthermore, iNOS mRNA
and nNOS mRNA remained undetectable in the COX1/
mutant.
Localisation of cyclooxygenase and PGE synthase
isoforms
As previously reported in the lamb (Coceani et al., 2001),
muscle cells from the wild-type mouse ductus showed greater
immunogold reactivity for COX1 than COX2 (Figure 2a).
Likewise, both enzymes were preferentially located in the
perinuclear rather than the peripheral region of the cytoplasm,
often in association with vesicular structures (Figure 2a). In
contrast, cPEGS and mPGES were similarly expressed and
were also distributed diffusely across the cytosol (Figure 2b).
Figure 3 provides representative examples of COX (a–d) and
PGES (e, f) antigenicity in ductus muscle cells. In those
instances in which the two groups of enzymes had concomi-
tantly been tagged, COX1- and COX2-linked gold particles
Figure 1 Gel electrophoresis of RT–PCR-amplified COX (upper
panel) and eNOS (lower panel) isoforms of mRNA in the foetal
ductus arteriosus from wild-type (WT) mice. Note that the level of
eNOS transcript was normalised to that of cyclophilin and did not
change upon COX1 deletion (lower panel). COX2/ animals were
not used since they behave as the COX1/ animals in showing an
enhanced NOS-based relaxing activity (see text and Figure 8).
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were found to be colocalised with mPGES-linked particles in
both the inner (Figure 4a and b) and the outer (Figure 4c and
d) regions of the cytoplasm. However, at either site, the
incidence of COX2/mPGES complexes (6.571.1 and
7.372.6%, respectively, in the perinuclear and peripheral
cytoplasm) exceeded greatly that of the COX1/mPGES
complexes (0.2570.1 and 0.370.15%, respectively, in the
perinuclear and peripheral cytoplasm). No obvious evidence,
on the other hand, was found of either COX being linked with
cPGES.
In vitro studies
The isolated ductus arteriosus was relatively small in the COX
mutant compared to the wild-type control, the lesser size being
particularly evident in the case of COX2 deletion (Table 1). In
agreement with a previous study (Coceani et al., 1999), the
wild-type vessel contracted variably during the initial period of
equilibration, and the steady tension being attained in 40–
60min was, as expected (see Methods), moderately greater at
12.5 than 2.5% O2 (0.3670.07mNmm
1, n¼ 10 vs
0.2070.03mNmm1, n¼ 16; Po0.05). Comparable values of
tension were observed with COX-deleted animals. However,
more often than in controls (80 vs 30% of experiments), their
baseline tone had transient contractions of uneven amplitude
(0.1–0.47mNmm1) and/or phasic discharges superimposed.
Whatever the genotype, the ductus contracted promptly to the
TXA2 analogue ONO-11113 (0.1 mm) (Figure 5), but the
magnitude of the contraction (at 2.5% O2) was slightly smaller
with COX2/ (0.8370.19mNmm1, n¼ 5; Po0.05) than
with either COX1/ (1.5270.08mNmm1, n¼ 4) or wild-
type (1.2370.08mNmm1, n¼ 10) preparations.
Indomethacin (2.8 mm) had a contractile effect on the vessel
and, in the case of the wild-type and the COX1/ mutant,
this response developed after short latency (2–7min) and
proceeded rapidly to a peak. As shown in Figure 5, the
progression of the contraction was often biphasic in the wild-
type, while in the COX1/ it was linear most of the times. In
contrast, the contractile response of the COX2/ ductus to
indomethacin was delayed in onset (32–67min) and slow in
development, with transient contractions often superimposed
on the rising slope (Figure 5). The peak contraction, once
attained (70–140min, mean 104), was sustained and showed
no significant difference in magnitude with the genotype
(Figure 6a and b). However, reversal of the contraction upon
washing out the inhibitor was complete, or nearly complete,
with the COX1/ ductus, while with the COX2/ vessel it
was partial (avg. 43%) or absent altogether (three of eight
exps.). Significantly, in the latter case, the vessel regained its
elevated tone even after being relaxed with SNP (100mm; see
Methods). The wild-type preparation, on the other hand,
behaved most variably after stopping the treatment with
indomethacin and showed complete reversal of the contraction
(five of 12 exps), partial reversal (avg. 58%) with or without
the SNP priming, or total lack of reversibility (four of 12
exps.). No obvious difference from the wild-type was noted
instead in the COX2þ / preparation with regard to both
magnitude (0.96 and 0.5770.10mNmm1 at 2.5 and 12.5%
O2, respectively; n¼ 2 and 3) and pattern of the indomethacin
contraction.
Contrary to indomethacin, l-NAME (100 mm) caused a
small and gradually developing contraction in the wild-type
preparation (Figure 7a). Only occasionally did the rising tone
have transient contractions and/or phasic discharges super-
imposed. The resulting peak response (in 50–150min, mean
97), as shown in Figure 8, was about one-third of that to
indomethacin (compare with Figure 6) and did not change
with the oxygen tension of the medium. However, upon
deleting either COX, the contraction to l-NAME became
greater, hence equalling in magnitude the indomethacin
contraction (Figure 8). Its shape was similar in the two null
mutants and consisted of an initial gradual rise in tone, often
with transient contractions superimposed, which after variable
delay (25–90min, mean 56) changed into an abrupt, secondary
contraction (Figure 7b). Exceptionally did the fast contraction
occur immediately after the start of the l-NAME treatment.
Whatever the pattern, the response of COX-deleted prepara-
tions to l-NAME was characterised by frequent bursts of
phasic activity. An enhanced effect of l-NAME was seen
even with preparations heterozygous for the COX2
deletion, their contraction being 0.7170.12mNmm1 (n¼ 6)
and 0.7670.12mNmm1 (n¼ 3), respectively, at 2.5 and
12.5% O2.
In vivo studies
The ductus was patent in all foetuses (Figure 9, upper panel)
and no difference in either maximal or minimal lumen area was
noted depending on the genotype (Figure 10). Likewise, in
both wild-type and COX-deleted animals, the vessel con-
stricted rapidly during the first 3 h after vaginal delivery
(Figure 9, lower panel) and closure, or virtual closure, was
attained by 12 h (Figure 10). Within this period, maximal
narrowing occurred in either, or both, the central and aortic
portions of the ductus, thus leaving the pulmonary end wider
throughout the closing process.
Figure 2 Transmission immunoelectron microscopy from the
muscle layer of the foetal mouse ductus arteriosus at term (n¼ 4).
(a) COX1 and COX2 immunogold labelling of the whole cytoplasm
(cyt) and its perinuclear and peripheral components. Note that gold
particle size was different in the two analyses (whole cytoplasm:
5 nm; perinuclear/peripheral cytoplasm: 10 nm). (b) Immunogold
labelling for microsomal and cytosolic PGE synthase (mPGES and
cPGES). *vs cytoplasm perinuclear, Po0.05 (Student’s t-test); wvs
COX1, whole cytoplasm, Po0.01 (Student’s t-test).
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Figure 3 Transmission electron micrograph of ultrathin cryosections from the muscle layer of the foetal mouse ductus arteriosus.
(a) Immunogold labelling for COX1; note the gold particles being clustered in the cytoplasm (indicated with arrows) which
surrounds the nucleus (N) and in the plasma membrane (arrowheads). (b) Immunogold labelling for COX1 in the peripheral
cytoplasm; label (arrows) is not as dense as that seen in the perinuclear cytoplasm. (c) Immunogold labelling for COX2 in the
perinuclear cytoplasm; note clusters of label in proximity of the nucleus (N). (d) Immunogold labelling for COX2; note few clusters
of label (arrows) in the peripheral cytoplasm and along the plasma membrane. (e) Immunogold labelling for cytosolic PGE
synthase; label was scattered throughout the cytoplasm (asterisks). (f) Immunogold labelling for microsomal PGE synthase; label
was found diffusely throughout the perinuclear (N) and peripheral cytoplasm (asterisks). Bar represents 0.25 mm (panels a, c, e, f) or
0.5mm (panels b and d).
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Figure 4 Transmission electron micrograph of ultrathin cryosections from the muscle layer of the foetal mouse ductus arteriosus.
(a) Dual immunogold labelling for COX1 (particle, 10 nm) and microsomal PGE synthase (particle, 5 nm); note colocalisation of the
two labels (arrows) in vesicle-like structures close to the nucleus (N). (b) Dual immunogold labelling for COX2 (particle, 10 nm) and
microsomal PGE synthase (particle, 5 nm); colocalisation of the two labels (arrows) in proximity of the nucleus (N). (c) Dual
immunogold labelling for COX1 (particle, 10 nm) and microsomal PGE synthase (particle, 5 nm) in the peripheral cytoplasm;
colocalisation of the two labels in vesicle-like structures (arrows). (d) Dual immunogold labelling for COX2 (particle, 10 nm) and
microsomal PGE synthase (particle, 5 nm) in the peripheral cytoplasm; colocalisation of the two labels (arrows). Note that in both
perinuclear and peripheral cytoplasm, COX2 colocalised more frequently than COX1 with microsomal PGE synthase. Bar
represents 0.1 mm.
Figure 5 Representative responses to indomethacin in the wild-type (WT) vs COX-deleted foetal mouse ductus arteriosus.
Contraction to the TXA2 analogue, ONO-11113, given as a reference. Length of the vessel is 540, 444 and 481mm (short side, see
Methods) for wild-type, COX1/ and COX2/, respectively.
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Discussion
In contrast to previous reports (Reese et al., 2000; Loftin et al.,
2001), this study demonstrates the presence of both COX
enzymes, COX1 and COX2, in the foetal mouse ductus. The
same vessel is also endowed with the two isoforms of PGES.
Hence, the mouse shares with other species, specifically the
lamb (Coceani et al., 2001; C. Ackerley and F. Coceani,
unpublished data), a complete system for PGE2 synthesis with
its two sets of enzymes being unevenly distributed within the
cell. In fact, in both species COX enzymes have primarily a
perinuclear location, while PGES enzymes are scattered
diffusely across the cytosol. Accordingly, the isolated mouse
ductus, as an equivalent preparation from the lamb (Smith,
1998), contracts forcefully to indomethacin. Significant in this
context is the fact that the guinea-pig ductus, which is
peculiarly unresponsive to indomethacin and other nonster-
oidal anti-inflammatory drugs (Coceani et al., 1978), has
exceedingly low levels of either COX (avg.o4 particles mm2),
lacking in addition any particular regional localisation, while
coincidentally it presents a full complement of PGES enzymes
(C. Ackerley and F. Coceani, unpublished data). From these
data, one may conclude that an appropriately high and region-
selective expression of COX enzymes is required for attaining
values of PGE2 synthesis effective on ductal muscle. COX1
and COX2, however, differ in their susceptibility to indo-
methacin, and this raises intriguing questions on their
individual operation. Leaving aside the latter point, our study
confirms that NO is naturally formed in the ductus and also
shows that the compound, despite its seemingly weak action
under normal conditions, may become important for ductus
Figure 6 Comparison of contractile responses to indomethacin
(2.8 mm) in the isolated ductus arteriosus from wild-type (WT) vs
COX-deleted mouse foetus. (a) 2.5% O2; (b) 12.5% O2. Wall tension
(mNmm1) prior to treatment, respectively, at 2.5 and 12.5% O2,
was as follows: WT, 0.3670.04 and 0.3670.15; COX1/,
0.3070.03 and 0.2970.13; COX2/, 0.2570.08 and 0.3670.03.
For each group, the number of experiments is given above each
column, and no significant difference between wild-type and COX-
deleted preparations is reached at either O2 tension. A significant
difference in the panel (a) relative to COX1/ is indicated with
*Po0.05 (ANOVA). Note that in the case of wild-type and
COX1/ preparations, responses are slightly lower at 12.5 than
2.5% O2 (Po0.05).
Figure 7 Representative response to l-NAME in the wild-type vs
COX-deleted foetal mouse ductus arteriosus. (a) wild-type; (b)
COX1/mutant. Note that response pattern is similar in COX1/
 and COX2/. Length of the vessel is 540 and 548mm (short side,
see Methods) for wild-type and COX1/, respectively.
Figure 8 Comparison of contractile responses to l-NAME
(100 mm) in the isolated ductus arteriosus from wild-type (WT) vs
COX-deleted mouse foetus. (a) 2.5% O2; (b) 12.5% O2. Wall tension
(mNmm1) prior to treatment, respectively, at 2.5 and 12.5% O2,
was as follows: WT, 0.0770.03 and 0.3770.04; COX1/,
0.2470.1 and 0.1470.08; COX2/, 0.0870.05 and 0.270.12.
For each group, the number of experiments is given above the
columns, and a significant difference (Po0.01) between wild-type
and COX-deleted preparations is indicated with an asterisk.
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patency should the efficacy of PGE2 abate for any reason.
Indeed, the marked enhancement in the l-NAME contraction
upon deletion of either COX implies a complementary role for
the two agents, whereby interference with the PGE2 mechan-
ism generates a signal for NO upregulation conceivably at the
post-transcriptional level (see Results). eNOS appears to be the
only NO-forming enzyme in the ductus and, in that respect,
the mouse differs from the lamb where both iNOS (Clyman
et al., 1998) and nNOS (Mason et al., 1999; Rairigh et al.,
2000) have also been detected. Based on this premise, the
discussion will address two issues: the reason for the
differential response of COX1 vs COX2 to indomethacin,
and the implications, conceptual and practical, from NO
upregulation subsequent to COX removal.
The uneven development of the indomethacin contraction in
COX1/ (rapid) vs COX2/ (slow) preparations is
unexpected and reveals a new aspect in the operation of
individual COX isoforms. Its knowledge is important particu-
larly when dealing with structures, as the one being considered
here, where both isoforms are constitutively expressed. Our
finding is unlikely linked to methodological factors such as the
accessibility of the target to the inhibitor or the effect of any
NO upregulation on the capability of the ductus to contract.
The wall of the vessel is exceedingly thin in all animals,
whether wild-type or COX-deficient (see Table 1), and should
allow a facile diffusion of indomethacin across the tissue.
Furthermore, there are no obvious differences in the sub-
cellular distribution of the two COX enzymes that could
account for their uneven susceptibility to the inhibitor. An
activated NO system, on the other hand, may well curtail the
contractile drive of the vessel but its influence, if potent
enough, should be equally evident with the COX1/ and
COX2/ genotypes. Therefore, it is safe to conclude that
differences in the response to indomethacin reside in the actual
operation of the enzymes. One possibility is that the COX/
indomethacin interaction varies with the isoform. Indeed, it
has been shown that, despite the lack of any isoform-linked
diversity in the occupancy of the catalytic site by indometha-
cin, inhibition is slower and not complete with COX1
compared to COX2 (Laneuville et al., 1994). Accordingly,
the indomethacin effect may need some time to reach the point
at which PGE2 formation falls below a critical level for the
maintenance of ductus relaxation. Alternatively, the observed
differences could be related not to the COX enzymes
themselves, but rather to the way such enzymes are opera-
tionally coupled with the PGES enzymes. Of relevance in this
connection is our finding (see Results) that COX1 is
colocalised minimally with mPGES and seemingly not at all
with cPGES. Conversely, there is the frequent coexistence of
COX2 with mPGES, hence implying preferential formation of
Figure 9 Cross-section of the ductus arteriosus and the large blood vessels in the wild-type and COX-deleted frozen mice. (upper
panel) Foetus at 19 days gestation; (lower panel) newborn at 3 h. WT, wild-type; DA, ductus arteriosus; Ao, aorta; PA, pulmonary
artery. Scale bar, 250 mm.
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PGE2 through a functional coupling of these enzymes. In
addition, it must be pointed out that a second mPGES (i.e.
mPGES2), to be distinguished from the conventional synthase
studied by us and now renamed mPGES1, has been
characterised in both foetal and adult tissues (Tanikawa
et al., 2002). The presence of mPGES2, should it be
ascertained in the ductus, may provide a new route, perhaps
isoform-specific, for PGE2 synthesis. Clearly, all these
possibilities are not mutually exclusive and their verification
warrants further investigation.
Whatever the reason for the differential behaviour of the
COX enzymes, our results may explain the reported inability
to observe a COX1-based contraction of the ductus in vivo
when indomethacin (Loftin et al., 2001) or a selective inhibitor
(Loftin et al., 2002) is given to the mother. Possibly, a delayed
responsiveness coupled with the inevitable fall of drug
levels with time might have hindered the detection of the
enzyme.
While certain facts concerning COX function remain to be
elucidated, our findings validate the role of NO as an
alternative agent to PGE2 in maintaining ductus patency. In
fact, it would appear that the two agents are intertwined
operationally to the point that even a fractional suppression of
COX function, as it happens in the COX2þ / genotype,
promotes the activation of the NO mechanism. The existence
of this efficient synergism raises several questions. For
example, it has been shown by us (see Results) and others
(Loftin et al., 2001) that the ductus remains patent in utero
after removal of either COX and, intuitively, the absence of
any change has been ascribed to compensation by the residual
enzyme. However, the rebound upregulation of NO could also
account, at least in part, for this finding. Clearly, in view of our
data, the persistent ductus patency in foetuses missing both
COXs (Reese et al., 2000; Loftin et al., 2001) is expected to rely
on an efficient NO mechanism. It remains to be ascertained
whether the indomethacin-resistant patency seen in animals
without the EP4 receptor subtype for PGE2 (Nguyen et al.,
1997; Kobayashi & Narumiya, 2002) is also linked to the same
process of compensation. An additional outstanding question
is whether inhibition of COX by pharmacological means may
mimic the gene deletion in promoting NO. Findings in another
vascular district of the perinatal animal support this possibility
(Zhang & Leffler, 2001). Any such occurrence in the ductus
would have important implications for the interpretation of
experimental and clinical data. It could provide an explanation
for the apparent loss of efficacy of a COX inhibitor as ductus
constrictor when the administration is chronic rather than
acute (Loftin et al., 2002). In addition, the observation of a
higher incidence of persistent ductus in infants from mothers
treated antenatally with indomethacin (Norton et al., 1993)
could find a reason in the overriding action of NO. In fact, if
one extends this reasoning further, a pharmacologically driven
rebound of NO could become an important causative factor
with any failure of the indomethacin therapy in prematures
with persistent ductus.
In conclusion, this study demonstrates the presence in the
mouse ductus of a complete enzyme system for the synthesis of
PGE2 including both COX1 and COX2. COX enzymes differ
in their susceptibility to the inhibitor action of indomethacin
and this finding may denote distinct functional properties.
However, despite this difference, deletion of either COX results
in the acceleration of NO synthesis. A cooperative interaction
between PGE2 and NO is expectedly important for ductus
patency in the foetus and may be a significant factor for
persistence of the vessel in the sick infant.
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